The U.S. Department of Veterans Affairs will be replacing Humira with the biosimilar Hadlima on its national formulary, as announced by Organon. Hadlima is a TNF inhibitor indicated for the treatment of various conditions and became the fourth FDA-approved biosimilar to Humira in 2019. The drug is available in a pre-filled syringe or an autoinjector, and Organon CEO Kevin Ali praised the VA for its leadership in championing biosimilars. CVS Caremark, one of the largest pharmacy benefit managers, also announced its intent to remove Humira from its major national commercial formularies in favor of biosimilar options. This is expected to increase the U.S. biosimilar market from less than $10 billion in 2022 to over $100 billion by 2029.
Source link
US Veterans Affairs to replace Humira with biosimilar on national formulary
